Active Biotech to Present at Jefferies 2014 Healthcare Conference

        Print
| Source: Active Biotech AB
Lund, Sweden, June 3, 2014 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is
scheduled to present at Jefferies 2014 Healthcare Conference held June
2-5, 2014 in New York, US. During the presentation, an update regarding Active
Biotech's development programs will be provided.

The presentation will include the laquinimod project, a novel oral
immunomodulatory drug primarily for the treatment of multiple sclerosis,
licensed to Teva Pharmaceutical, the Phase III prostate cancer project
tasquinimod in co-development with Ipsen, as well as ANYARA, Active Biotech's
novel concept for tumor therapy of primarily renal cell cancer. Also, the
project with paquinimod (57-57) and the pre-clinical ISI project will be
presented.

The audio and slide presentation will be webcasted live and can be accessed via
the Active Biotech web site. To access the live and replay presentations please
go to - www.activebiotech.com.

The presentation will take place on June 3, at 4:30 p.m. EDT / 10:30 p.m. CEST.


For further information, please contact:
Hans Kolam, CFO
Phone: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com



About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. In pivotal phase is
laquinimod, an orally administered small molecule with unique immunomodulatory
properties for the treatment of multiple sclerosis. Also tasquinimod for the
treatment of prostate cancer, with an unique mode of action, is in pivotal
phase. In addition, laquinimod has concluded Phase II development for Crohn's
and Lupus. The company has two additional projects in clinical development,
ANYARA primarily for the treatment of renal cell cancer and the orally
administered compound paquinimod (57-57) for systemic sclerosis. Please visit
www.activebiotech.com for more information.

 Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00


Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication 08:30 a.m. CET on June 3, 2014.


[HUG#1790029]